Chronic Subdural Hematoma (cSDH) Identified
CT showing chronic (hypodense/isodense) extra-axial collection
All Pathways
NeurosurgeryManagement
Chronic Subdural Hematoma - Surgical Management (SVIN 2025)
Chronic Subdural Hematoma - Surgical Management (SVIN 2025): Chronic Subdural Hematoma (cSDH) Identified → Symptomatic? → Symptomatic - Evaluate for Sur...
Pathway Overview
16 steps
Algorithm Steps
16 total
01Start 02Decision Symptomatic?
Assess for symptoms requiring intervention
- Headache
- Cognitive decline/confusion
- Gait disturbance
- Focal weakness
- Speech difficulty
- Seizures
03Action Symptomatic - Evaluate for Surgery
Most symptomatic patients benefit from surgery
04Decision On Anticoagulation/Antiplatelets?
Common in elderly cSDH population
05Action Anticoagulation Management
Hold/reverse prior to surgery
- Hold warfarin, give Vitamin K ± PCC
- Hold DOACs (half-life dependent)
- Hold aspirin: controversial, often continued
- Dual antiplatelet: hold P2Y12 if possible
- Platelet transfusion rarely needed
06Decision Surgical Approach
Select based on hematoma characteristics
07Action Burr Hole Drainage
Most common approach (SVIN 2025 consensus)
- 1-2 burr holes over collection
- Irrigate until clear
- Place subdural drain (24-48h)
- Drain reduces recurrence
- Similar outcomes to craniotomy
08Decision Consider MMA Embolization?
Middle meningeal artery embolization per SVIN 2025 Consensus
- EMBOLISE: 4.1% vs 11.3% recurrence (p=0.008)
- STEM: 16% vs 36% recurrence (OR 0.36)
- MAGIC-MT: 6.7% vs 9.9% recurrence
- Can be done with or after surgery
- Especially for high recurrence risk
09Action MMA Embolization (SVIN 2025)
Reduces recurrence by ~50% per RCT data (Class I evidence)
- Onyx, Squid, or n-BCA embolic agents
- Can be done at time of surgery or after
- Fewer serious adverse events vs surgery alone
- SVIN: 'may become standard of care'
- EMPROTECT 2025: confirms benefit in high-risk
10Action Post-Operative Care
Standard post-craniotomy management
- Subdural drain for 24-48h
- Flat positioning (controversial)
- Hydration to promote brain re-expansion
- Repeat CT before discharge
- Seizure prophylaxis (institution-dependent)
11Decision Recurrence?
Recurrence rate 5-30%
12Action Recurrence Management
Options for recurrent cSDH
- Repeat burr hole drainage
- MMA embolization (if not done)
- Craniotomy with membrane removal
- Address underlying factors (anticoag, atrophy)
13Outcome Resolution
Follow-up imaging to confirm resolution; resume anticoagulation per indication
- Path rejoins step 10Shared downstream outcome
14Action Craniotomy
Consider for organized/septated hematoma
- Better for loculated collections
- Allows membrane removal
- Higher morbidity than burr hole
- Reserved for complex cases
- Path rejoins step 08Shared downstream outcome
15Action Twist Drill Craniostomy
Bedside option for poor surgical candidates
- Can be done at bedside
- Lower anesthesia risk
- Higher recurrence rate
- For patients unfit for OR
- Path rejoins step 08Shared downstream outcome
- Path rejoins step 06Shared downstream outcome
16Action Asymptomatic/Minimal Symptoms
Consider observation for small, asymptomatic cSDH
- Serial imaging q2-4 weeks
- Monitor for symptom development
- Many resolve spontaneously
- Address anticoagulation if applicable
- Path rejoins step 13Shared downstream outcome
Guideline Source
SVIN Consensus Statement on Middle Meningeal Artery Embolization in Chronic Subdural Hematoma Treatment (2025)
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Anticoagulation resumption timing remains controversial
- MMA embolization not available at all centers
- Optimal drain duration not standardized
- Bilateral cSDH may require staged approach
- Does not address pediatric populations
Contraindicated Populations
pediatric
Applicable Regions
USEUGlobal
EU: Similar surgical approaches, local variation in MMA availability
US: MMA embolization increasingly available
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Chronic Subdural Hematoma - Surgical Management (SVIN 2025)?
The Chronic Subdural Hematoma - Surgical Management (SVIN 2025) is a management clinical algorithm for Neurosurgery. It provides a structured decision tree to guide clinical decision-making, based on SVIN Consensus Statement on Middle Meningeal Artery Embolization in Chronic Subdural Hematoma Treatment (2025).
What guideline is the Chronic Subdural Hematoma - Surgical Management (SVIN 2025) based on?
This algorithm is based on SVIN Consensus Statement on Middle Meningeal Artery Embolization in Chronic Subdural Hematoma Treatment (2025) (DOI: 10.1161/SVIN.125.001814).
What are the limitations of the Chronic Subdural Hematoma - Surgical Management (SVIN 2025)?
Known limitations include: Anticoagulation resumption timing remains controversial; MMA embolization not available at all centers; Optimal drain duration not standardized; Bilateral cSDH may require staged approach; Does not address pediatric populations. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Chronic Subdural Hematoma - Surgical Management (SVIN 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free